Zheng J X, Li X Z, Xiang R L, Gao Z
Department of Thoracic Surgery, Beijing Friendship Hospital, Capital Medical University, Beijing, China.
Indian J Cancer. 2015 Nov;52 Suppl 1:e37-40. doi: 10.4103/0019-509X.168955.
The incidence of synchronous lung tumors is rare, as reported in various clinical series, ranging from 0.2% to 8%. Most reported cases of synchronous tumors were shown to have the same histologic types of lung cancer. Among possible combinations, squamous cell carcinoma was by far the most common. Primary pulmonary lymphoma (PPL) is very rare in clinics accounting for only 0.5-1% of primary lung tumors. There is no report about synchronous primary pulmonary adenocarcinoma presenting with lung lymphoma. It can be easily misdiagnosed or missed. Although the treatment of PPL and synchronous pulmonary tumors has controversial, surgery with/without postoperative adjuvant radio-chemotherapy are used for most patients in present. We describe a case of synchronous primary lung tumors presenting with lymphoma and adenocarcinoma, in which expression of the cell surface antigens were evaluated immunohistochemically. By taking into consideration of the reported experiences, the author discusses the clinical features, prognostic criteria and therapeutic management of synchronous lung cancer and PPL.
如各种临床系列报道所示，同时性肺肿瘤的发生率很低，为0.2%至8%。大多数报道的同时性肿瘤病例显示为相同组织学类型的肺癌。在可能的组合中，鳞状细胞癌是迄今为止最常见的。原发性肺淋巴瘤（PPL）在临床上非常罕见，仅占原发性肺肿瘤的0.5-1%。目前尚无关于同时性原发性肺腺癌合并肺淋巴瘤的报道。它很容易被误诊或漏诊。尽管PPL和同时性肺肿瘤的治疗存在争议，但目前大多数患者采用手术加/不加术后辅助放化疗的方法。我们描述了一例同时性原发性肺肿瘤合并淋巴瘤和腺癌的病例，其中通过免疫组织化学评估了细胞表面抗原的表达。结合已报道的经验，作者讨论了同时性肺癌和PPL的临床特征、预后标准及治疗处理。
